Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
ADC Therapeutics SA is a clinical-stage biotechnology company focused on the development and commercialization of antibody–drug conjugate (ADC) therapies for the treatment of hematologic malignancies and solid tumors. The company operates within the biopharmaceutical and oncology therapeutics industries, with its core strategy centered on leveraging proprietary ADC technology to deliver highly potent cytotoxic agents directly to cancer cells.
The company’s primary revenue driver is Zynlonta® (loncastuximab tesirine), an FDA-approved ADC for the treatment of certain forms of relapsed or refractory diffuse large B‑cell lymphoma (DLBCL). ADC Therapeutics was founded in 2011 as a spin-out from academic research conducted at the Swiss Federal Institute of Technology Lausanne (EPFL) and has since evolved into a publicly traded company listed on the NYSE under the ticker ADCT, advancing multiple ADC candidates through clinical development.
Business Operations
ADC Therapeutics’ operations are organized around the research, development, regulatory approval, and commercialization of ADC-based oncology drugs. Its core business activities include discovery and preclinical research, clinical development, manufacturing oversight, and commercialization, with revenues currently derived primarily from U.S. sales of Zynlonta®. The company does not manufacture products at scale internally and relies on third-party contract manufacturing organizations for drug substance and drug product production.
The company’s technology platform combines proprietary Pyrrolobenzodiazepine (PBD) dimer warheads, linker technologies, and monoclonal antibodies to create targeted ADC therapies. ADC Therapeutics maintains strategic collaborations with academic institutions and commercial partners to support clinical trials and manufacturing but does not currently report material joint ventures. Its operating subsidiaries include ADC Therapeutics (America), Inc., which manages U.S. commercial and clinical operations.
Strategic Position & Investments
Strategically, ADC Therapeutics is focused on expanding the commercial footprint of Zynlonta® while advancing a pipeline of next-generation ADC candidates, including camidanlumab tesirine and other preclinical programs targeting both hematologic cancers and solid tumors. Growth initiatives emphasize label expansion, combination therapy studies, and development of novel ADC constructs with improved therapeutic indices.
The company has invested significantly in internal R&D rather than large-scale acquisitions, prioritizing capital allocation toward clinical trials and platform innovation. Its pipeline assets are wholly or majority owned, and the company retains global development and commercialization rights for its key programs. Emerging focus areas include improved linker chemistry and alternative payload technologies designed to enhance safety and efficacy profiles.
Geographic Footprint
ADC Therapeutics is headquartered in Lausanne, Switzerland, with significant operational presence in the United States, where its commercial, regulatory, and clinical development activities are primarily based. The company’s U.S. operations are centered in New Jersey and New York, supporting oncology commercialization and clinical trial management.
Commercially, Zynlonta® is marketed in the United States, while international expansion efforts include regulatory and clinical activities in Europe and selected global markets. Clinical trials are conducted across North America, Europe, and parts of Asia-Pacific, reflecting the company’s multinational development strategy and global patient recruitment efforts.
Leadership & Governance
ADC Therapeutics is led by an executive team with experience in oncology drug development, commercialization, and global biopharmaceutical operations. The leadership emphasizes a strategy focused on scientific rigor, disciplined capital deployment, and advancing targeted cancer therapies with meaningful clinical benefit.
Key executives include:
- Christopher J. Martin – Chief Executive Officer
- Thomas Fuchs – Chief Financial Officer
- Dr. Paul R. Wotton – President and Chief Operating Officer
- Dr. Andreas Wicki – Chief Medical Officer
- Dr. Jeffrey A. Northrup – Chief Scientific Officer
The company is governed by a board of directors with backgrounds in biotechnology, finance, and pharmaceutical regulation, overseeing corporate strategy, risk management, and shareholder interests.